Skip to content
http://lifestyle.matomyseo.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Connect Biopharma Holdings Limited
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
March 30, 2026
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
March 30, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
March 3, 2026
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
←
Previous Page
1
2